Novo Nordisk Chases Oral Obesity Market as CagriSema Data and Pipeline Deals Face Investor Scrutiny
Published on 09/27/2026 at 13:11 | Editorial boerse-global.de
Novo Nordisk is betting that the future of obesity treatment will not be injected but swallowed. CEO Mike Doustdar told Reuters on Tuesday that oral formulations could capture as much as half of the global market for weight-loss medicines by 2030, a projection that has prompted the Danish drugmaker to reorient both its clinical development and its commercial strategy around that shift.
The company's shares, however, have yet to reflect much of that optimism. Novo Nordisk closed Friday at EUR 34.05, down 23 percent since the start of the year and roughly 38 percent below its 52-week high of EUR 54.86.
Clinical Data Under the Microscope
At the center of the debate are Phase 3 results for CagriSema, released on September 21. In adults with type-2 diabetes, the combination therapy delivered a 12.4 percent average weight reduction after roughly 60 weeks of treatment, compared with 9.1 percent for Eli Lilly's tirzepatide. A separate study in adults with obesity showed a 21 percent weight loss at a 1.0 mg dose versus placebo. Novo Nordisk has said it will now align the regulatory pathway for the type-2 diabetes indication with health authorities, and management is targeting a market launch for early next year.
That efficacy edge of just over three percentage points gives the Danes a visible advantage — one that still has to prove itself in the eyes of regulators and physicians. If Novo Nordisk can demonstrate that the clinical benefit comes without a tolerability penalty, it would cement the foundation for the post-semaglutide era. Should the therapeutic gap be perceived as marginal, the company's premium-pricing power would come under pressure.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
A Pipeline Built on Partnerships
To reinforce its product portfolio, Novo Nordisk has been acquiring external technology. On Friday, it signed a global licensing and cooperation agreement with Swedish firm Nanexa covering the PharmaShell delivery technology, spanning up to five long-acting injection programs. The deal carries a total value of up to EUR 1.165 billion, of which EUR 615 million consists of upfront, development and regulatory milestone payments. Novo Nordisk will handle worldwide development and commercialization.
Tablet-based therapies are advancing in parallel. On September 17, the company struck a licensing and development agreement with Orbis Medicines worth up to USD 1.4 billion to research oral treatments for cardiometabolic diseases. Since September 16, Novo Nordisk has also been working with Anthropic to test Claude models in drug discovery and clinical documentation.
Internally, Doustdar called on staff on September 15 to embed a stronger customer focus. A day earlier, the company introduced the everyday name "Novo" and the guiding philosophy "Novo Way," while the official corporate designation Novo Nordisk A/S remains unchanged.
Growth Targets Meet a Skeptical Market
Management used its capital markets day to set a goal of bringing more than five multi-blockbuster products to market by 2030, alongside an ambition of generating risk-adjusted pipeline revenue exceeding DKK 150 billion by 2035. Yet the company itself has acknowledged that its 2030 targets carry uncertainties and do not constitute a binding financial forecast.
Analysts are not uniformly convinced. Evan Seigerman of BMO noted that annual revenue growth of 3.6 percent is already priced into the stock. On Tuesday, CFRA downgraded Novo Nordisk's US depositary receipts from Hold to Sell, setting a price target of USD 38. Intensifying price competition and looming patent expirations add to the pressure, and a faster-than-expected slowdown in market growth would put the operating margin to the test.
The Next Catalyst in Milan
Attention now turns to the European Association for the Study of Diabetes annual meeting in Milan from September 28 to October 2, where Novo Nordisk will present 44 papers on semaglutide, CagriSema and Zenagamtid. The details unveiled there will serve as the next gauge of whether the company's research pipeline can carry the weight placed upon it. As long as regulatory progress on CagriSema stays on track and the efficacy data hold up in direct comparison, Novo Nordisk retains a potent counterweight to competitive pressure. Should confidence in its pricing power falter or approval steps slip, the stock's downward trend looks likely to persist.
Ad
Novo Nordisk Stock: New Analysis - 27 September
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
